** Brokerage UBS cuts PT on drugmaker Regeneron Pharmaceuticals REGN.O to $560 from $633
** UBS says it has removed smoker's lung drug, itepekimab, from "current collaboration pipeline given the regulatory uncertainty and potential competitor entries"
** Company and partner Sanofi SASY.PA said last week that their experimental drug, itepekimab, failed in a late-stage trial, testing it for a lung disease commonly called "smoker's lung", but met the goal of another trial for the same disease
** UBS says REGN will have higher operating expenses in the near-to-mid term due to integrating 23andMe and increased R&D for obesity treatments
** However, UBS expects these costs to decrease after 2030
** "Eylea franchise weakness remains a key overhang for our near-term REGN thesis" - UBS
** Including session's move, REGN down 31.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。